Their findings, published March 25 in the journal Cell Host & Microbe, increase understanding of the molecular drivers of C. diff infection and point to novel therapeutic strategies. C.

The ongoing trial is testing the therapy – RBX2660 – as a treatment for Clostridioides difficile infection or C. diff, a bacterium that causes diarrhoea and inflammation in the colon and is a ...

The superbug Clostridioides difficile, or C. diff, can cause dangerous gut infections ... However, given the lack of testing, this likely isn't the whole story." To find out whether the bacteria ...

RBX2660 has been granted Orphan Drug status, Fast Track status and gained Breakthrough Therapy Designation from the FDA in October 2015 for its potential to prevent recurrent C. diff. infection.